Cargando…

Biological Role of MYCN in Medulloblastoma: Novel Therapeutic Opportunities and Challenges Ahead

The constitutive and dysregulated expression of the transcription factor MYCN has a central role in the pathogenesis of the paediatric brain tumour medulloblastoma, with an increased expression of this oncogene correlating with a worse prognosis. Consequently, the genomic and functional alterations...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shrestha, Sumana, Morcavallo, Alaide, Gorrini, Chiara, Chesler, Louis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236857/ https://www.ncbi.nlm.nih.gov/pubmed/34195095 http://dx.doi.org/10.3389/fonc.2021.694320

Ejemplares similares

MBRS-57. IDENTIFICATION OF MYC-DEPENDENT THERAPEUTIC VULNERABILITIES FOR TARGETING GROUP 3 MEDULLOBLASTOMA
por: Llargués-Sistac, Gemma, et al.
Publicado: (2020)

Molecular and In Vivo Characterization of Cancer-Propagating Cells Derived from MYCN-Dependent Medulloblastoma
por: Ahmad, Zai, et al.
Publicado: (2015)

MEDB-79. MYC-driven upregulation of thede novo serine and glycine pathway is a novel therapeutic target for Group 3 MYC-amplified Medulloblastoma
por: Adiamah, Magretta, et al.
Publicado: (2022)

Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer
por: Cage, Tene Aneka, et al.
Publicado: (2015)

MYCN and the epigenome
por: He, Stanley, et al.
Publicado: (2013)

Pharmacogenetics – Challenges and Opportunities Ahead
por: Zanger, Ulrich M.
Publicado: (2010)

MBRS-33. TEMPORARY RESTORATION OF p53 ACTIVITY DURING FRACTIONATED RADIOTHERAPY IN A GROUP3 MEDULLOBLASTOMA GEMM REPRESENTS A POWERFUL TOOL FOR RADIOBIOLOGY STUDIES
por: Morcavallo, Alaide, et al.
Publicado: (2020)

OMIC-03. TRANSLATIONAL CONTROL IN MYC AND MYCN MEDULLOBLASTOMA
por: Schmidt, Christin, et al.
Publicado: (2021)

Targeting MYCN and ALK in resistant and relapsing neuroblastoma
por: Tucker, Elizabeth R, et al.
Publicado: (2019)

MYCN Function in Neuroblastoma Development
por: Otte, Jörg, et al.
Publicado: (2021)

Metastasis in neuroblastoma: the MYCN question
por: Bhavsar, Swapnil Parashram
Publicado: (2023)

A Novel Mechanism of 17-AAG Therapeutic Efficacy on HSP90 Inhibition in MYCN-Amplified Neuroblastoma Cells
por: Hanna, Reine, et al.
Publicado: (2021)

MODL-02. A novelCre-conditionalcMYC-driven MB Group 3 transgenic mouse model shows traceable leptomeningeal dissemination.
por: Morcavallo, Alaide, et al.
Publicado: (2022)

Editorial: Targeting MYCN in Pediatric Cancers
por: Sala, Arturo
Publicado: (2015)

Molecular Mechanisms of MYCN Dysregulation in Cancers
por: Liu, Ruochen, et al.
Publicado: (2021)

Targeting MYCN in Pediatric and Adult Cancers
por: Liu, Zhihui, et al.
Publicado: (2021)

NLRR1 Is a Potential Therapeutic Target in Neuroblastoma and MYCN-Driven Malignant Cancers
por: Takatori, Atsushi, et al.
Publicado: (2021)

MYCN mRNA degradation and cancer suppression by a selective small-molecule inhibitor in MYCN-amplified neuroblastoma
por: Liu, Tao, et al.
Publicado: (2022)

p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance
por: Chen, Lindi, et al.
Publicado: (2012)

ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma
por: Huynh, Tony, et al.
Publicado: (2012)

MYCN: from oncoprotein to tumor-associated antigen
por: Pistoia, Vito, et al.
Publicado: (2012)

The MicroRNA Landscape of MYCN-Amplified Neuroblastoma
por: Misiak, Danny, et al.
Publicado: (2021)

Molecular mechanisms of MYCN-dependent apoptosis and the MDM2–p53 pathway: an Achille’s heel to be exploited for the therapy of MYCN-amplified neuroblastoma
por: Petroni, Marialaura, et al.
Publicado: (2012)

Editorial: Molecular Mechanisms and Treatment of MYCN-Driven Tumors
por: Suenaga, Yusuke, et al.
Publicado: (2021)

Targeting MYCN in Molecularly Defined Malignant Brain Tumors
por: Borgenvik, Anna, et al.
Publicado: (2021)

Patient Engagement in Kidney Research: Opportunities and Challenges Ahead
por: Molnar, Amber O., et al.
Publicado: (2017)

Biologics as novel therapeutics for the treatment of allergy: Challenges and opportunities
por: Atanasio, Amanda, et al.
Publicado: (2022)

MYCN-mediated transcriptional repression in neuroblastoma: the other side of the coin
por: Gherardi, Samuele, et al.
Publicado: (2013)

CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma
por: Sussman, Robyn T., et al.
Publicado: (2020)

Reciprocal Induction of MDM2 and MYCN in Neural and Neuroendocrine Cancers
por: Tran, Hung N., et al.
Publicado: (2020)

Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges
por: Sklavenitis-Pistofidis, Romanos, et al.
Publicado: (2022)

MEDB-36. Clinical and molecular heterogeneity withinMYC andMYCN amplified medulloblastoma
por: Schwalbe, Edward, et al.
Publicado: (2022)

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors
por: Vaughan, Lynsey, et al.
Publicado: (2016)

The Tara Oceans Project: New Opportunities and Greater Challenges Ahead
por: Zhang, Houjin, et al.
Publicado: (2015)

Future technologies and techniques in peritoneal dialysis—opportunities and challenges ahead
por: Holmes, Clifford J., et al.
Publicado: (2008)

Mental Healthcare Act 2017 – The way ahead: Opportunities and Challenges
por: Jagadish, A., et al.
Publicado: (2019)

Processing of Complex Materials in the Copper Industry: Challenges and Opportunities Ahead
por: Flores, Gerardo Alvear, et al.
Publicado: (2020)

The Upcoming Role for Nursing and Assistive Robotics: Opportunities and Challenges Ahead
por: Christoforou, Eftychios G., et al.
Publicado: (2020)

Non-Genomic Control of Dynamic MYCN Gene Expression in Liver Cancer
por: Qin, Xian-Yang, et al.
Publicado: (2021)

The Insulin and IGF-I Pathway in Endocrine Glands Carcinogenesis
por: Malaguarnera, Roberta, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_s4stkjlt7eav1gsk88s8ga0ib8